Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GATA3 antisense RNA 1 (GATA3-AS1)
- Target
- GATA3-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Epigenetic regulator
01
Overview
GATA3 antisense RNA 1 (GATA3-AS1) is a divergent long non-coding RNA located adjacent to the GATA3 gene, sharing its promoter. It is selectively expressed in TH2 cells and required for efficient transcription of GATA3 and key cytokine genes (IL5, IL13). GATA3-AS1 acts by recruiting MLL methyltransferase to its locus through an R-loop structure, facilitating chromatin modification and transcriptional activation under TH2 differentiation. Dysregulation of GATA3-AS1 has been implicated in various cancers, where it promotes cell proliferation, migration, invasion, immune evasion (via PD-L1 stabilization), and epithelial–mesenchymal transition. Elevated levels of GATA3-AS1 are associated with tumor progression and poor chemotherapy response. It is considered both a mechanistic driver and a potential biomarker in cancers and immune disorders
- Other names
- GATA3-AS1GATA3 antisense RNA 1
02
Mechanism of action
siRNA-mediated knockdown of GATA3-AS1 reduces GATA3 and downstream cytokine expression. Modulation of chromatin structure through interaction with MLL methyltransferase. Targeting GATA3-AS1 may impair tumor proliferation, migration, invasion, and immune escape.
03
Biological functions
Regulation of gene transcription, particularly GATA3Chromatin remodeling and formation of permissive chromatin marks (H3K27 acetylation, H3K4 methylation)T helper cell (TH2) differentiation and immune response regulationRegulation of cell proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) in cancerImmune escape (via regulating PD-L1 stability)
04
Disease associations
Cancer (including triple-negative breast cancer, pancreatic cancer, hepatocellular carcinoma, bladder cancer)Immune modulation (TH2 differentiation, allergies, asthma)
05
Safety considerations
As a non-coding RNA target, safety profiles remain undeveloped; lncRNA targeting may have off-target or unpredictable epigenetic effectsPotential for immune dysregulation if targeted in autoimmune or allergic disease settingsUntested in clinical contexts, so therapeutic challenges remain mostly speculative
06
Biomarkers
GATA3-AS1 expression level as a predictive biomarker for chemotherapy response in breast cancerGATA3-AS1 as a marker of TH2 cell polarization in immunological disorders
Beyond the preview
Go deeper on GATA3 antisense RNA 1 (GATA3-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GATA3 antisense RNA 1 (GATA3-AS1).